News coverage about Natera (NASDAQ:NTRA) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Natera earned a news impact score of 0.21 on Accern’s scale. Accern also assigned media stories about the medical research company an impact score of 44.0696952656334 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news articles that may have impacted Accern Sentiment’s analysis:

NTRA has been the subject of several recent research reports. Zacks Investment Research upgraded Natera from a “sell” rating to a “buy” rating and set a $9.25 price target for the company in a research report on Thursday, August 10th. Cowen and Company reiterated a “buy” rating and issued a $14.00 price target on shares of Natera in a research report on Friday, September 1st. BidaskClub upgraded Natera from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd. Morgan Stanley dropped their price target on Natera from $18.00 to $13.00 and set an “overweight” rating for the company in a research report on Monday, August 7th. Finally, ValuEngine upgraded Natera from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 10th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $14.45.

Shares of Natera (NTRA) traded down 0.23% during mid-day trading on Friday, reaching $12.89. 72,210 shares of the company’s stock traded hands. Natera has a 12-month low of $7.88 and a 12-month high of $13.49. The stock’s market capitalization is $686.04 million. The company’s 50-day moving average price is $13.02 and its 200-day moving average price is $13.02.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Tuesday, August 8th. The medical research company reported ($0.52) earnings per share for the quarter, meeting the consensus estimate of ($0.52). Natera had a negative net margin of 62.64% and a negative return on equity of 137.46%. The business had revenue of $53.60 million during the quarter, compared to analysts’ expectations of $50.57 million. During the same quarter in the prior year, the company posted ($0.46) EPS. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. Analysts anticipate that Natera will post ($2.03) earnings per share for the current year.

In other news, insider Jonathan Sheena sold 120,000 shares of the stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $12.54, for a total value of $1,504,800.00. Following the completion of the sale, the insider now owns 533,208 shares of the company’s stock, valued at approximately $6,686,428.32. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 12.57% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Natera (NTRA) Stock Price” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at

Natera Company Profile

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.